Neurology sits at a strange intersection in 2026: the brain remains the least well-understood major organ system, yet the past three years have produced some of the most significant drug approvals in medicine — lecanemab and donanemab slowing Alzheimer's progression, tofersen modifying ALS course in a genetically defined subgroup, gene therapies for spinal muscular atrophy that have reshaped the entire disease trajectory for children diagnosed early. The momentum is real. So is what remains unsolved: Parkinson's neuroprotection has still not arrived despite decades of promising targets, traumatic brain injury remains without disease-modifying treatment, and ALS prognosis outside the SOD1 and FUS subgroups remains largely unchanged. The trial landscape in 2026 reflects both the genuine progress and the distance still to travel.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Lecanemab (Leqembi, 2023) and donanemab (Kisunla, 2024) slowed cognitive decline by 27–35% in early Alzheimer's disease with confirmed amyloid pathology — the first disease-modifying approvals. GLP-1 agonists are now in Phase 3 neurology trials (EVOKE, LIRAGLUTIDE-AD2) based on epidemiological data showing 40–70% lower neurodegeneration rates in GLP-1 users. Tofersen (Qalsody) modified ALS course in SOD1-ALS; the presymptomatic ATLAS trial uses plasma NfL biomarker to intervene before symptoms — a historic first. BTK inhibitor tolebrutinib (HERCULES) showed the first positive Phase 3 result in progressive MS. Platform trial designs (HEALEY ALS, Alzheimer's master protocols) are accelerating drug evaluation across all neurological conditions.
ClinicalMetric Analysis
- Lecanemab and donanemab's 27–35% cognitive decline slowing applies to a precisely defined population that most dementia patients presenting to community neurology don't currently meet without additional diagnostic workup. Both drugs require confirmed amyloid pathology by PET or CSF before treatment — not a clinical diagnosis of Alzheimer's alone. APOE4 homozygotes face ARIA microhemorrhage rates up to 42% and require genotyping and enhanced MRI surveillance protocols. The real-world implementation gap isn't drug availability — it's the amyloid PET infrastructure (expensive, variably covered) and the genetic counseling capacity for APOE4 disclosure that most community neurology practices can't currently provide. Patients interested in these treatments should ask specifically about amyloid confirmation testing options and APOE4 testing at their institution, not just whether the drug is "available."
- GLP-1 agonists' 40–70% lower neurodegeneration rates in observational data are striking but require confounding control that database studies can't adequately provide — the EVOKE and LIRAGLUTIDE-AD2 Phase 3 trials are the decisive test, not the epidemiological associations. The people on GLP-1 agonists in large database studies are T2D patients who were metabolically managed well enough to qualify for and adhere to weekly injections — a selected, healthier subgroup than all T2D patients. This selection bias plausibly explains a meaningful fraction of the observed neurodegeneration difference independent of any direct drug effect. EVOKE's randomized design (semaglutide vs. placebo in early Alzheimer's) provides the causal evidence the observational data cannot, and results expected 2027 will substantially clarify whether GLP-1's neuroprotection signal is a drug effect or a confound.
- Tofersen's ATLAS trial design — presymptomatic intervention using plasma NfL as a biomarker entry criterion in SOD1-ALS carriers — is the most methodologically important neurology trial design in years, and its framework is directly applicable to other genetic neurodegenerative diseases. If ATLAS demonstrates that tofersen reduces plasma NfL rise and delays symptom onset in presymptomatic SOD1 carriers, it establishes that a liquid biomarker of neurodegeneration can serve as a trial entry criterion for presymptomatic disease-modification — not just a monitoring tool. LRRK2-PD, GRN-FTD, MAPT-FTD, and other genetic neurodegenerative diseases where plasma NfL rises predictably before symptom onset are all candidates for the same presymptomatic intervention design. The ATLAS result is consequential beyond ALS specifically.
Alzheimer's Disease: Beyond Amyloid Clearance
The 2023 approval of lecanemab (Leqembi) and 2024 approval of donanemab (Kisunla) represent a genuine inflection in Alzheimer's research — not a cure, but the first drugs that slow the neurodegenerative process rather than only managing symptoms. Both are anti-amyloid antibodies that clear amyloid plaques from the brain. Lecanemab targets protofibrils (a particularly toxic intermediate form of amyloid); donanemab targets mature plaques with pyroglutamate modification. CLARITY AD (lecanemab): 27% slowing of cognitive decline on CDR-SB over 18 months. TRAILBLAZER-ALZ 2 (donanemab): 35% slowing, and notably, 47% slowing in patients with low/medium tau burden — suggesting that earlier intervention with less tau pathology may be where the clearest benefit occurs.
The 2026 trials are moving earlier. AHEAD 3-45 enrolls cognitively unimpaired adults with elevated amyloid to test lecanemab in presymptomatic Alzheimer's — the central prevention hypothesis that is the most important unanswered question in the field. TRAILBLAZER-ALZ 3 asks the same question with donanemab. The AACG trial and others are testing subcutaneous formulations to replace monthly IV infusions. What's critical for patients: ARIA (amyloid-related imaging abnormalities — microhemorrhages and edema) is a real safety concern with both drugs, risk is higher in APOE4 carriers, and patient selection requires amyloid PET or CSF confirmation of amyloid pathology before treatment.
GLP-1 agonists have emerged as the most surprising neuroprotection candidate in neurology. Epidemiological database studies show semaglutide users have 40–70% lower rates of Alzheimer's diagnosis, Parkinson's disease, and stroke — associations that are highly consistent across multiple large datasets. The mechanistic candidates are multiple: GLP-1 receptor activation reduces neuroinflammation, improves cerebrovascular function, reduces tau phosphorylation in preclinical models, and drives weight loss which independently reduces dementia risk. EVOKE (semaglutide 2.4mg vs. placebo in early Alzheimer's, NCT05021588) and LIRAGLUTIDE-AD2 Phase 3 are directly testing this hypothesis; results expected 2027.
Parkinson's Disease: Gene Therapy and the Alpha-Synuclein Problem
Parkinson's disease remains without a disease-modifying therapy despite 30 years of research and numerous promising targets. The fundamental challenge: dopaminergic neuron loss is irreversible, and the window for treatment may be years before diagnosis — by the time patients have symptoms, 60–70% of dopaminergic neurons in the substantia nigra are gone.
Alpha-synuclein — the misfolded protein that forms Lewy bodies and propagates prion-like through neural circuits — remains the primary target. Passive immunization trials with anti-alpha-synuclein antibodies (cinpanemab, prasinezumab) have been disappointing in Phase 2, but the field hasn't abandoned the target; it's reconsidering whether antibodies can reach intracellular alpha-synuclein efficiently enough. Antisense oligonucleotides (ASOs) targeting SNCA mRNA are entering Phase 1/2 — they work intracellularly, which may be mechanistically more appropriate. UB-312, an active vaccine generating antibodies against a specific alpha-synuclein conformation, is in Phase 2.
Gene therapy for monogenic PD forms is more advanced. BIIB094 (an ASO targeting LRRK2 mRNA) is in the REASON Phase 1/2 for LRRK2-mutant PD. GDNF gene therapy (Asklepios AGTC-110, AAV2-GDNF delivered via MRI-guided convection-enhanced injection into the putamen) is in Phase 2 — attempting to restore trophic support to degenerating dopaminergic neurons. Earlier GDNF trials failed due to delivery problems; convection-enhanced delivery directly into brain parenchyma is a more rational approach. Focused ultrasound thalamotomy for PD tremor (SONIFICATION Phase 3) provides symptom relief rather than neuroprotection but has reached Phase 3 following FDA approval for essential tremor.
ALS: The ATLAS Trial and the Biomarker Era
The approval of tofersen (Qalsody) for SOD1-ALS in 2023 was ALS research's most meaningful milestone in years. SOD1 mutations account for roughly 2% of all ALS cases — a small subgroup, but one where an antisense oligonucleotide delivered intrathecally could reduce toxic misfolded SOD1 protein and slow disease progression. The VALOR trial showed slower decline on functional scales with clear biomarker support from plasma NfL (neurofilament light chain) reduction.
What makes the ATLAS trial historic is the presymptomatic intervention concept. ATLAS enrolls adults with pathogenic SOD1 variants who are asymptomatic but showing NfL elevation in plasma — a biomarker signal that precedes clinical symptoms by months to years. This is the first trial to test ALS therapy before symptoms appear, using a blood biomarker to identify the intervention window. It directly parallels the Alzheimer's prevention trial concept. If positive, it would establish a template for genetic-risk-based early intervention in ALS that could extend to C9orf72, FUS, and other genetic forms.
The HEALEY ALS Platform Trial at Massachusetts General Hospital is the most efficient ongoing ALS drug evaluation system. It operates as a perpetual master protocol: multiple treatments enter simultaneously, are tested against a shared control arm, and cycle through as results emerge. Current arms include zilucoplan (complement C5 inhibitor), CNM-Au8 (gold nanocrystal neuronal energy support), and reldesemtiv (skeletal troponin activator). The platform design allows ALS trials to complete faster and with smaller sample sizes than traditional designs — critical in a disease where survival is measured in months to years and traditional trial enrollment takes years.
Stroke Recovery and Neuroprotection
Stroke trial research in 2026 is focused on three areas: extending the treatment window, neuroprotection in the acute phase, and rehabilitative enhancement in recovery.
Tenecteplase is replacing alteplase as the preferred thrombolytic following AcT and NOR-TEST trials showing non-inferiority with single-bolus dosing (vs. alteplase's 60-minute infusion) — a meaningful practical advantage in the acute stroke setting. The TIMELESS trial is testing tenecteplase in patients presenting 4.5–24 hours from onset who have salvageable tissue on perfusion imaging — an effort to extend the treatment window using imaging-based patient selection rather than time cutoffs.
For recovery, brain stimulation plus intensive physical therapy is the most clinically promising combination: transcranial direct current stimulation or repetitive TMS applied to the motor cortex during physical therapy sessions appears to augment neuroplasticity synergistically. EVEREST-2 and NICHE Phase 3 trials are evaluating epidural cortical stimulation. STEM20 and BrainSTAR are evaluating mesenchymal stem cells (IV infusion of modified MSCs) in subacute and chronic ischemic stroke, aiming to promote endogenous neural repair through growth factor secretion and modulation of the post-stroke inflammatory environment.
Key Takeaways
- Alzheimer's prevention trials (AHEAD 3-45, TRAILBLAZER-ALZ 3) are enrolling cognitively unimpaired adults with elevated amyloid — the definitive test of whether amyloid clearance before symptoms produces durable dementia prevention.
- ATLAS for presymptomatic SOD1-ALS uses plasma NfL biomarker to identify intervention timing before symptom onset — the first presymptomatic ALS trial and a template for future genetic-risk-based neurological disease prevention.
- GLP-1 agonists (semaglutide EVOKE, liraglutide LIRAGLUTIDE-AD2) are in Phase 3 Alzheimer's trials based on epidemiological signals of 40–70% lower neurodegeneration rates — possibly the most surprising neuroprotection candidate in the field.
- Tolebrutinib HERCULES showed the first positive Phase 3 result in non-relapsing secondary progressive MS — a population without any effective treatment until now.
- Platform trial designs — HEALEY ALS, Alzheimer's master protocols, MS sequential networks — are compressing neurological drug development timelines by testing multiple agents simultaneously against shared controls.